
Biotech, Medical Device & Pharma Startup News
Get news straight to your inbox by signing up for our free eNewsletters
3/27/2023
Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced today the appointment of Thomas Ichim, Ph.D., as President, and Chief Executive Officer of Campbell Neurosciences.
3/21/2023
Enveric Biosciences today announced that it has established Enveric Therapeutics Pty. Ltd., an Australia-based subsidiary, to support the Company’s plans to advance its EVM201 Series, including lead candidate EB-373, towards the clinic.
3/6/2023
Starlight Therapeutics Inc., a Lantern subsidiary, will focus exclusively on the clinical development of therapies for CNS (central nervous system) and brain cancers with limited or no effective therapeutic options.
3/6/2023
Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research, development and sublicense agreement with Grifols (Nasdaq: GRFS), a global leader in plasma-derived medicines, for the development and commercialization of immunoglobulin eye drops for dry eye disease.
2/28/2023
Zymtronix, Inc., a groundbreaking new biotechnology company, today announced that Dr. Thomas Videbaek, biotech industry veteran and former Executive Vice President (EVP) of Novozymes, is joining its Board of Directors.
2/1/2023
FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, announced they are the fastest rising biotech offering in StartEngine’s history surpassing $1 million of new investments on the first day of its Reg CF offering.
1/30/2023
Swedish medtech startup Syntach AB has been awarded up to €15 million in equity financing by European Innovation Council (EIC) for the development of the Syntach Cardiac Support System, a breakthrough device for patients with heart failure.
1/19/2023
Selux Diagnostics announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary Next Generation Phenotyping (NGP) System.
1/17/2023
Oncotelic Therapeutics, Inc announced the launch of Pet2DAO Inc., a wholly owned subsidiary of Oncotelic, and its associated token PDAO.
1/17/2023
TTP plc (TTP), a leading independent technology and product development company, has today announced the launch of Cellular Origins, a TTP Company.
3/21/2023